|
Gene: NECTIN2 |
Gene summary for NECTIN2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NECTIN2 | Gene ID | 5819 |
Gene name | nectin cell adhesion molecule 2 | |
Gene Alias | CD112 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92692 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5819 | NECTIN2 | P76T-E | Human | Esophagus | ESCC | 8.84e-05 | -2.34e-01 | 0.1207 |
5819 | NECTIN2 | P79T-E | Human | Esophagus | ESCC | 4.17e-05 | -2.34e-01 | 0.1154 |
5819 | NECTIN2 | P130T-E | Human | Esophagus | ESCC | 1.88e-04 | -2.34e-01 | 0.1676 |
5819 | NECTIN2 | NAFLD1 | Human | Liver | NAFLD | 6.76e-03 | 3.93e-01 | -0.04 |
5819 | NECTIN2 | HCC1_Meng | Human | Liver | HCC | 4.06e-02 | -8.79e-02 | 0.0246 |
5819 | NECTIN2 | cirrhotic1 | Human | Liver | Cirrhotic | 1.93e-02 | -8.79e-02 | 0.0202 |
5819 | NECTIN2 | HCC1 | Human | Liver | HCC | 5.21e-09 | 3.40e+00 | 0.5336 |
5819 | NECTIN2 | HCC2 | Human | Liver | HCC | 8.46e-14 | 2.74e+00 | 0.5341 |
5819 | NECTIN2 | Pt14.d | Human | Liver | HCC | 4.06e-02 | -8.79e-02 | 0.0143 |
5819 | NECTIN2 | S014 | Human | Liver | HCC | 2.11e-30 | 1.06e+00 | 0.2254 |
5819 | NECTIN2 | S015 | Human | Liver | HCC | 6.04e-34 | 1.71e+00 | 0.2375 |
5819 | NECTIN2 | S016 | Human | Liver | HCC | 4.44e-27 | 1.06e+00 | 0.2243 |
5819 | NECTIN2 | S027 | Human | Liver | HCC | 9.51e-33 | 2.08e+00 | 0.2446 |
5819 | NECTIN2 | S028 | Human | Liver | HCC | 2.25e-56 | 2.15e+00 | 0.2503 |
5819 | NECTIN2 | S029 | Human | Liver | HCC | 1.42e-59 | 2.68e+00 | 0.2581 |
5819 | NECTIN2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 5.61e-04 | 3.18e-01 | 0.3371 |
5819 | NECTIN2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.77e-05 | 4.77e-01 | 0.343 |
5819 | NECTIN2 | RNA-P17T-P17T-6 | Human | Lung | IAC | 3.17e-04 | 5.65e-01 | 0.3385 |
5819 | NECTIN2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.40e-08 | 5.90e-01 | 0.3329 |
5819 | NECTIN2 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.48e-05 | 1.42e-01 | -0.0132 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
GO:00507929 | Breast | Precancer | regulation of viral process | 27/1080 | 164/18723 | 7.59e-07 | 3.05e-05 | 27 |
GO:00444099 | Breast | Precancer | entry into host | 25/1080 | 151/18723 | 1.74e-06 | 6.19e-05 | 25 |
GO:00467189 | Breast | Precancer | viral entry into host cell | 24/1080 | 144/18723 | 2.46e-06 | 8.35e-05 | 24 |
GO:00439039 | Breast | Precancer | regulation of biological process involved in symbiotic interaction | 15/1080 | 72/18723 | 1.23e-05 | 3.17e-04 | 15 |
GO:19039009 | Breast | Precancer | regulation of viral life cycle | 23/1080 | 148/18723 | 1.31e-05 | 3.30e-04 | 23 |
GO:00523727 | Breast | Precancer | modulation by symbiont of entry into host | 12/1080 | 49/18723 | 1.61e-05 | 3.93e-04 | 12 |
GO:00465964 | Breast | Precancer | regulation of viral entry into host cell | 11/1080 | 42/18723 | 1.83e-05 | 4.35e-04 | 11 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:00027117 | Breast | Precancer | positive regulation of T cell mediated immunity | 12/1080 | 56/18723 | 6.72e-05 | 1.35e-03 | 12 |
GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
GO:00019168 | Breast | Precancer | positive regulation of T cell mediated cytotoxicity | 8/1080 | 29/18723 | 1.73e-04 | 2.83e-03 | 8 |
GO:00027094 | Breast | Precancer | regulation of T cell mediated immunity | 13/1080 | 85/18723 | 1.12e-03 | 1.23e-02 | 13 |
GO:00019146 | Breast | Precancer | regulation of T cell mediated cytotoxicity | 8/1080 | 39/18723 | 1.48e-03 | 1.53e-02 | 8 |
GO:00019134 | Breast | Precancer | T cell mediated cytotoxicity | 9/1080 | 49/18723 | 1.74e-03 | 1.74e-02 | 9 |
GO:00024563 | Breast | Precancer | T cell mediated immunity | 14/1080 | 109/18723 | 3.97e-03 | 3.15e-02 | 14 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0452024 | Breast | DCIS | Adherens junction | 17/846 | 93/8465 | 9.95e-03 | 4.40e-02 | 3.24e-02 | 17 |
hsa0452034 | Breast | DCIS | Adherens junction | 17/846 | 93/8465 | 9.95e-03 | 4.40e-02 | 3.24e-02 | 17 |
hsa045202 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
hsa045203 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
hsa045208 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
hsa045209 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
hsa0452025 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
hsa04520111 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
hsa0452026 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
hsa0452035 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0452014 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
hsa0452015 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
hsa0452022 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
hsa0452032 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
hsa0452042 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0452052 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Breast | ADJ |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Breast | ADJ |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Breast | ADJ |
CD226 | NECTIN2 | CD226_NECTIN2 | CD226 | Breast | ADJ |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Breast | DCIS |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Breast | DCIS |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Breast | DCIS |
CD226 | NECTIN2 | CD226_NECTIN2 | CD226 | Breast | DCIS |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Breast | Healthy |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Breast | Healthy |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Breast | Precancer |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Breast | Precancer |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Cervix | ADJ |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Cervix | ADJ |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Cervix | ADJ |
CD226 | NECTIN2 | CD226_NECTIN2 | CD226 | Cervix | ADJ |
NECTIN3 | NECTIN2 | NECTIN3_NECTIN2 | NECTIN | Cervix | CC |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Cervix | CC |
NECTIN2 | TIGIT | NECTIN2_TIGIT | NECTIN | Cervix | CC |
TIGIT | NECTIN2 | TIGIT_NECTIN2 | TIGIT | Cervix | CC |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NECTIN2 | SNV | Missense_Mutation | rs533933961 | c.1330N>A | p.Ala444Thr | p.A444T | Q92692 | protein_coding | tolerated(0.31) | benign(0) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | |
NECTIN2 | SNV | Missense_Mutation | c.584C>T | p.Ser195Phe | p.S195F | Q92692 | protein_coding | deleterious(0.02) | probably_damaging(0.951) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
NECTIN2 | SNV | Missense_Mutation | c.136N>G | p.Leu46Val | p.L46V | Q92692 | protein_coding | tolerated(0.08) | probably_damaging(0.928) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
NECTIN2 | SNV | Missense_Mutation | c.909N>A | p.Phe303Leu | p.F303L | Q92692 | protein_coding | tolerated(1) | benign(0.001) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
NECTIN2 | SNV | Missense_Mutation | rs752088661 | c.853N>A | p.Val285Ile | p.V285I | Q92692 | protein_coding | tolerated(0.1) | benign(0.149) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NECTIN2 | SNV | Missense_Mutation | rs138153191 | c.736N>A | p.Glu246Lys | p.E246K | Q92692 | protein_coding | tolerated(0.38) | benign(0.014) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NECTIN2 | SNV | Missense_Mutation | rs768454344 | c.772C>T | p.Arg258Cys | p.R258C | Q92692 | protein_coding | tolerated(0.16) | possibly_damaging(0.872) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NECTIN2 | SNV | Missense_Mutation | novel | c.1583N>G | p.Lys528Arg | p.K528R | Q92692 | protein_coding | deleterious(0.02) | benign(0.283) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
NECTIN2 | SNV | Missense_Mutation | rs373335144 | c.148N>A | p.Val50Met | p.V50M | Q92692 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NECTIN2 | SNV | Missense_Mutation | rs773746451 | c.665N>A | p.Arg222His | p.R222H | Q92692 | protein_coding | tolerated(0.54) | benign(0.121) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |